First-line drug recommended by guidelines for the treatment of multiple myeloma and myelodysplastic syndrome
Lenalidomide is a new generation of immunomodulatory anti-tumor drug with a wide range of mechanisms of action, including anti-tumor angiogenesis and improving immune function and bone marrow microenvironment. It is clinically used in the treatment of multiple myeloma, lymphoma, myelodysplastic syndrome, acute myeloid leukemia and other diseases, and is currently the first-line drug recommended by the guidelines for the treatment of multiple myeloma and myelodysplastic syndrome.
Indications:
Multiple myeloma in previously untreated adult patients who are not suitable for transplantation (in combination with dexamethasone).
Multiple myeloma in adult patients who have received at least one therapy (in combination with dexamethasone).
Follicular lymphoma (grade 1-3A) in previously treated adult patients (in combination with rituximab).
STRENGTH:
5mg
10mg
25mg
Download instructions
Contact us